AAPL344.66+5.16 (+1.52%) ▲|ABBV283.42-5.66 (-1.96%) ▼|ABT98.57-3.89 (-3.79%) ▼|ACN237.60-1.53 (-0.64%) ▼|ADBE255.28-1.45 (-0.56%) ▼|AMAT409.14+4.16 (+1.03%) ▲|AMD553.81+19.07 (+3.57%) ▲|AMGN437.33-1.61 (-0.37%) ▼|AMT178.95-4.61 (-2.51%) ▼|AMZN263.93+1.30 (+0.50%) ▲|AVGO338.58+4.21 (+1.26%) ▲|AXP323.66+5.32 (+1.67%) ▲|BA192.56+2.09 (+1.10%) ▲|BAC50.94+0.30 (+0.59%) ▲|BKNG158.82-5.10 (-3.11%) ▼|BLK1,142.09+13.41 (+1.19%) ▲|BMY60.82-0.87 (-1.40%) ▼|BNY146.54+2.29 (+1.59%) ▲|BRK-B542.08+2.26 (+0.42%) ▲|C123.61+1.10 (+0.90%) ▲|CAT741.55+16.31 (+2.25%) ▲|CL93.71-0.83 (-0.88%) ▼|CMCSA21.89-0.47 (-2.10%) ▼|COF208.30+6.74 (+3.34%) ▲|COP145.86-0.09 (-0.06%) ▼|COST996.30+1.69 (+0.17%) ▲|CRM242.29-0.14 (-0.06%) ▼|CSCO107.43+0.72 (+0.67%) ▲|CVS94.31-0.44 (-0.46%) ▼|CVX226.55+0.84 (+0.37%) ▲|DE632.65+0.45 (+0.07%) ▲|DHR230.57+6.33 (+2.82%) ▲|DIS111.38-0.29 (-0.26%) ▼|DUK121.06-0.28 (-0.23%) ▼|EMR164.95+4.49 (+2.80%) ▲|FDX299.55+0.79 (+0.26%) ▲|GD345.72+1.28 (+0.37%) ▲|GE298.48-1.39 (-0.46%) ▼|GEV928.88+38.55 (+4.33%) ▲|GILD153.46-3.05 (-1.95%) ▼|GM76.15-0.94 (-1.22%) ▼|GOOG330.45-5.95 (-1.77%) ▼|GOOGL334.59-5.69 (-1.67%) ▼|GS903.89+19.08 (+2.16%) ▲|HD314.43-0.68 (-0.22%) ▼|HON215.44+2.12 (+0.99%) ▲|IBM245.41+3.49 (+1.44%) ▲|INTC92.64+0.95 (+1.03%) ▲|INTU334.16-1.13 (-0.34%) ▼|ISRG429.84-8.16 (-1.86%) ▼|JNJ255.99-3.37 (-1.30%) ▼|JPM334.50-0.76 (-0.23%) ▼|KO92.67-0.82 (-0.88%) ▼|LIN502.06+0.17 (+0.03%) ▲|LLY1,270.37-13.29 (-1.04%) ▼|LMT548.75+0.04 (+0.01%) ▲|LOW196.54-0.75 (-0.38%) ▼|LRCX261.42-2.03 (-0.77%) ▼|MA623.34+2.92 (+0.47%) ▲|MCD245.86-0.66 (-0.27%) ▼|MDLZ62.47-1.53 (-2.38%) ▼|MDT93.52-1.11 (-1.17%) ▼|META707.79+13.54 (+1.95%) ▲|MMM174.01+2.64 (+1.54%) ▲|MO73.86-0.78 (-1.05%) ▼|MRK148.63+0.33 (+0.22%) ▲|MS184.97+4.57 (+2.53%) ▲|MSFT532.64+0.77 (+0.14%) ▲|MU917.85+21.78 (+2.43%) ▲|NEE78.69-0.18 (-0.22%) ▼|NFLX65.71-2.98 (-4.34%) ▼|NKE37.80-0.09 (-0.22%) ▼|NOW152.96+3.42 (+2.28%) ▲|NVDA221.37+4.90 (+2.26%) ▲|ORCL129.92-1.22 (-0.93%) ▼|PEP134.62+0.60 (+0.44%) ▲|PFE29.72-0.40 (-1.31%) ▼|PG157.73-1.59 (-1.00%) ▼|PLTR199.52+6.92 (+3.59%) ▲|PM196.84-3.07 (-1.53%) ▼|QCOM177.67+1.96 (+1.12%) ▲|RTX189.66-3.68 (-1.90%) ▼|SBUX98.74-0.64 (-0.64%) ▼|SCHW91.69+0.80 (+0.88%) ▲|SO90.53-0.18 (-0.20%) ▼|SPG206.14-0.85 (-0.41%) ▼|T21.96-1.46 (-6.23%) ▼|TMO694.24+6.87 (+1.00%) ▲|TMUS153.10-4.65 (-2.95%) ▼|TSLA386.45+12.74 (+3.41%) ▲|TXN288.23+10.45 (+3.76%) ▲|UBER68.23-0.72 (-1.04%) ▼|UNH417.32-1.94 (-0.46%) ▼|UNP289.18+1.57 (+0.55%) ▲|UPS100.18+1.66 (+1.68%) ▲|USB59.35+0.26 (+0.44%) ▲|V408.62+2.05 (+0.50%) ▲|VZ43.48-1.07 (-2.39%) ▼|WFC82.31+0.11 (+0.13%) ▲|WMT117.74-0.11 (-0.09%) ▼|XOM177.70-0.17 (-0.09%) ▼|AAPL344.66+5.16 (+1.52%) ▲|ABBV283.42-5.66 (-1.96%) ▼|ABT98.57-3.89 (-3.79%) ▼|ACN237.60-1.53 (-0.64%) ▼|ADBE255.28-1.45 (-0.56%) ▼|AMAT409.14+4.16 (+1.03%) ▲|AMD553.81+19.07 (+3.57%) ▲|AMGN437.33-1.61 (-0.37%) ▼|AMT178.95-4.61 (-2.51%) ▼|AMZN263.93+1.30 (+0.50%) ▲|AVGO338.58+4.21 (+1.26%) ▲|AXP323.66+5.32 (+1.67%) ▲|BA192.56+2.09 (+1.10%) ▲|BAC50.94+0.30 (+0.59%) ▲|BKNG158.82-5.10 (-3.11%) ▼|BLK1,142.09+13.41 (+1.19%) ▲|BMY60.82-0.87 (-1.40%) ▼|BNY146.54+2.29 (+1.59%) ▲|BRK-B542.08+2.26 (+0.42%) ▲|C123.61+1.10 (+0.90%) ▲|CAT741.55+16.31 (+2.25%) ▲|CL93.71-0.83 (-0.88%) ▼|CMCSA21.89-0.47 (-2.10%) ▼|COF208.30+6.74 (+3.34%) ▲|COP145.86-0.09 (-0.06%) ▼|COST996.30+1.69 (+0.17%) ▲|CRM242.29-0.14 (-0.06%) ▼|CSCO107.43+0.72 (+0.67%) ▲|CVS94.31-0.44 (-0.46%) ▼|CVX226.55+0.84 (+0.37%) ▲|DE632.65+0.45 (+0.07%) ▲|DHR230.57+6.33 (+2.82%) ▲|DIS111.38-0.29 (-0.26%) ▼|DUK121.06-0.28 (-0.23%) ▼|EMR164.95+4.49 (+2.80%) ▲|FDX299.55+0.79 (+0.26%) ▲|GD345.72+1.28 (+0.37%) ▲|GE298.48-1.39 (-0.46%) ▼|GEV928.88+38.55 (+4.33%) ▲|GILD153.46-3.05 (-1.95%) ▼|GM76.15-0.94 (-1.22%) ▼|GOOG330.45-5.95 (-1.77%) ▼|GOOGL334.59-5.69 (-1.67%) ▼|GS903.89+19.08 (+2.16%) ▲|HD314.43-0.68 (-0.22%) ▼|HON215.44+2.12 (+0.99%) ▲|IBM245.41+3.49 (+1.44%) ▲|INTC92.64+0.95 (+1.03%) ▲|INTU334.16-1.13 (-0.34%) ▼|ISRG429.84-8.16 (-1.86%) ▼|JNJ255.99-3.37 (-1.30%) ▼|JPM334.50-0.76 (-0.23%) ▼|KO92.67-0.82 (-0.88%) ▼|LIN502.06+0.17 (+0.03%) ▲|LLY1,270.37-13.29 (-1.04%) ▼|LMT548.75+0.04 (+0.01%) ▲|LOW196.54-0.75 (-0.38%) ▼|LRCX261.42-2.03 (-0.77%) ▼|MA623.34+2.92 (+0.47%) ▲|MCD245.86-0.66 (-0.27%) ▼|MDLZ62.47-1.53 (-2.38%) ▼|MDT93.52-1.11 (-1.17%) ▼|META707.79+13.54 (+1.95%) ▲|MMM174.01+2.64 (+1.54%) ▲|MO73.86-0.78 (-1.05%) ▼|MRK148.63+0.33 (+0.22%) ▲|MS184.97+4.57 (+2.53%) ▲|MSFT532.64+0.77 (+0.14%) ▲|MU917.85+21.78 (+2.43%) ▲|NEE78.69-0.18 (-0.22%) ▼|NFLX65.71-2.98 (-4.34%) ▼|NKE37.80-0.09 (-0.22%) ▼|NOW152.96+3.42 (+2.28%) ▲|NVDA221.37+4.90 (+2.26%) ▲|ORCL129.92-1.22 (-0.93%) ▼|PEP134.62+0.60 (+0.44%) ▲|PFE29.72-0.40 (-1.31%) ▼|PG157.73-1.59 (-1.00%) ▼|PLTR199.52+6.92 (+3.59%) ▲|PM196.84-3.07 (-1.53%) ▼|QCOM177.67+1.96 (+1.12%) ▲|RTX189.66-3.68 (-1.90%) ▼|SBUX98.74-0.64 (-0.64%) ▼|SCHW91.69+0.80 (+0.88%) ▲|SO90.53-0.18 (-0.20%) ▼|SPG206.14-0.85 (-0.41%) ▼|T21.96-1.46 (-6.23%) ▼|TMO694.24+6.87 (+1.00%) ▲|TMUS153.10-4.65 (-2.95%) ▼|TSLA386.45+12.74 (+3.41%) ▲|TXN288.23+10.45 (+3.76%) ▲|UBER68.23-0.72 (-1.04%) ▼|UNH417.32-1.94 (-0.46%) ▼|UNP289.18+1.57 (+0.55%) ▲|UPS100.18+1.66 (+1.68%) ▲|USB59.35+0.26 (+0.44%) ▲|V408.62+2.05 (+0.50%) ▲|VZ43.48-1.07 (-2.39%) ▼|WFC82.31+0.11 (+0.13%) ▲|WMT117.74-0.11 (-0.09%) ▼|XOM177.70-0.17 (-0.09%) ▼|
17.3 C
New York
Wednesday, October 21, 2026

Tag: safety profile

newsFORsourcecompanycontentinformation1releasesmarket

New Study Confirms LP815® Probiotic Reduces Canine Anxiety and Aggression

With behavioral issues affecting up to 85% of dogs, LP815 provides a clinically supported approach to ease anxiety, reduce aggression, and support more restful,...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

Ad hoc announcement pursuant to Art. 53 LR

2025 Report: “PurDentix Reviews and Complaints” Surge Reflects Growing Curiosity Around Oral Microbiome Supplements

Consumer Search Data Reveals Expanding Curiosity Around Oral Probiotics and Ingredient Transparency in 2025 
Consumer Search Data Reveals Expanding Curiosity Around Oral Probiotics and Ingredient Transparency in 2025

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

INSIDE INFORMATION
REGULATED INFORMATION

Femasys Announces Second Quarter Financial Results for 2025

-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio --

ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the second quarter of 2025.

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs)

Lilly reports second-quarter 2025 financial results and raises guidance

Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year...

Implantica announces second publication of groundbreaking 5-year results from the landmark RefluxStop® clinical study

VADUZ, Liechtenstein, Aug. 7, 2025 /PRNewswire/ -- Implantica AG (publ), a leading medtech company pioneering advanced implantable medical technologies, today announced the second peer-reviewed...

Robust eDNA Monitoring Finds No Significant Impact on Natural Marine Microbial Communities in Gigablue’s Field Experiment

Comprehensive eDNA analysis of open ocean experiment demonstrates minimal environmental disruption from proprietary substrate deployment 
Comprehensive eDNA analysis of open ocean experiment demonstrates minimal environmental disruption from proprietary substrate deployment

HYLENR Closes Pre-Series A Funding to Commercialise Low-Energy Nuclear Reaction Systems

The Pre-Series A Funding Marks Transition from Breakthrough Research to Prototyping, Validates LENR as a Scalable Clean Energy Alternative HYDERABAD, India, Aug. 6, 2025 /PRNewswire/...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSafety profile

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers